Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9920134B2 · kind B2 · utility
10Cited by
49References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2011 |
| Grant date | Mar 20, 2018 |
| Priority date | — |
| Expiry date | Jun 30, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.